Lipoprotein management

Brunzell JD et al Lipoprotein management in patients with cardiometabolic risk Consensus conference report from the ADA and the American College of Cardiology Foundation. 3 Am Coll Cardiol 2008 51(15) 1512. [PMID 18402913]... 

The expected outcomes for die patient may include a dierapeutic response to dierapy (lowered blood lipid levels), management of common adverse drug reactions, and an understanding of die dietary measures necessary to reduce lipid and lipoprotein levels. 

Distribution - Largely outside the blood volume approximately 33% to 47% is in plasma, 4% to 9% in lymphocytes, 5% to 12% in granulocytes and 41% to 58% in erythrocytes. In plasma, approximately 90% is bound to proteins, primarily lipoproteins. Blood level monitoring is useful in patient management. 

Primary chylomicronemia (familial lipoprotein lipase or cofactor deficiency) Chylomicrons, VLDL increased Dietary management (niacin, fibrate) Niacin plus fibrate... 

Devroey D, Vantomme K, Betz W, Vandevoorde J, Kartounian J (2004) A review of the treatment guidelines on the management of low levels of high-density lipoprotein cholesterol. Cardiology 102 61-66... 

D. Gal, M. Ohashi, P.C. MacDonald, H.J. Buchsbaum and E.R. Simpson, Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms, Am. J. Obstet. Gynecol. 139 (1981) 877-885. 

In this article we shall review recent advances in plasma lipoproteins, apolipoproteins, and those proteins concerned with lipoprotein lipid metabolism. This is a rapidly growing field, far too large to enable all aspects to be covered in a single paper. In order to keep to a manageable size, we shall focus on areas in which there have been recent major advances. Our treatment of other areas will be brief, as adequate reviews are in most cases available. Clinical details of primary disorders of plasma lipid metabolism are very well covered in a series of reviews in The Metabolic Basis of Inherited Disease (5th Ed., J. B. Stanbury, J. B. Wyngaarden, D. S. Fredrickson, J. L. Goldstein, and M. S. Brown, eds.) (B52, G13, G20, H24, N8, S3, S56). Disordered lipid metabolism, and especially secondary disorders of lipid metabolism, are equally well covered in Metabolic Control and Disease (8th Ed., P. K. Bondy and L. E. Rosenberg, eds.) (H16). 

Source Especially from Schaefer EJ and Levy RI. Pathogenesis and management of lipoprotein disorders. N Engl J Med 312 1300-11310, 1985. 

High-Density Lipoprotein Cholesterol, Plasma Triglyceride, and Coronary Heart Disease Pathophysiology and Management Wolfgang Patsch and Antonio M. Gotto, Jr. 

---